A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces
central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as
assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study
medication is administered via subcutaneous (under the skin) injections.